keyword
MENU ▼
Read by QxMD icon Read
search

ovarian biomarkers

keyword
https://www.readbyqxmd.com/read/28819419/osteopontin-a-promising-biomarker-for-cancer-therapy
#1
REVIEW
Ran Wei, Janet Pik Ching Wong, Hang Fai Kwok
Osteopontin (OPN), a multifunctional protein, has emerged as a potentially valuable biomarker for diagnosing and treating cancers. Recent research focuses on its involvement in tumor biology including the cell proliferation, survival, angiogenesis, invasion, and metastasis. Understanding the molecular mechanisms and pharmacological effects of OPN in cancer development could lead to new targets for improving cancer diagnosis and treatment. This review explains how the structurally conserved domains of OPN are associated with OPN signaling mediators and CD44, and how the conserved OPN domains determine biological functions...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28815456/recommendations-for-biomarker-testing-in-epithelial-ovarian-cancer-a-national-consensus-statement-by-the-spanish-society-of-pathology-and-the-spanish-society-of-medical-oncology
#2
A Oaknin, R Guarch, P Barretina, D Hardisson, A González, X Matías-Guiu, A Pérez-Fidalgo, B Vieites, I Romero, J Palacios
Because of advances in the understanding of histological and molecular characteristics in ovarian cancer, it is now possible to recognize the existence of five subtypes, which in turn has allowed a more refined therapeutic approach and better design of clinical trials. Each of these five subtypes has specific histological features and a particular biomarker expression, as well as mutations in different genes, some of which have prognostic and predictive value. CA125 and HE4 are examples of ovarian cancer biomarkers used in the diagnosis and follow-up of these malignancies...
August 16, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28815182/neutrophil-to-lymphocyte-ratio-is-a-potential-prognostic-biomarker-in-patients-with-ovarian-cancer-a-meta-analysis
#3
REVIEW
Shubo Chen, Liu Zhang, Guangyue Yan, Sijin Cheng, Abdel Hamid Fathy, Nana Yan, Yongzhao Zhao
BACKGROUND AND AIMS: Plenty of studies were conducted to explore the prognostic significance of neutrophil-to-lymphocyte ratio (NLR) in ovarian cancer with contradictory results. This study aims to summarize the prognostic significance of NLR in patients with ovarian cancer. METHODS: A literature search in PubMed, Cochrane Library, and Embase was conducted. The endpoints were progression-free survival (PFS) and overall survival (OS). RESULTS: Eleven studies involving a total of 2,892 patients were identified...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28807983/cancer-associated-pathways-and-biomarkers-of-venous-thrombosis
#4
Yohei Hisada, Nigel Mackman
Cancer patients have an increased risk of venous thromboembolism (VTE). In this review, we will summarize common and cancer type-specific pathways of VTE in cancer patients. Increased levels of leukocytes, platelets and tissue factor-positive (TF+) microvesicles are all potential factors that alone or in combination increase cancer-associated thrombosis. Lung and colorectal cancer patients often exhibit leukocytosis. Neutrophils could increase VTE in cancer patients by releasing neutrophil extracellular traps whereas monocytes may express TF...
August 14, 2017: Blood
https://www.readbyqxmd.com/read/28804555/imp3-is-upregulated-in-primary-ovarian-mucinous-carcinoma-and-promotes-tumor-progression
#5
Qin Zhu, Yuqing Qu, Qiongyan Zhang, Linghui Lu, Weiwei Weng, Hao Zhang, Lihong Zhang, Yan Ning, Yiqin Wang
OBJECTIVE: Primary ovarian mucinous tumors progress from benign adenoma to borderline tumors to invasive mucinous carcinoma. A proper differential diagnosis is crucial to discriminate malignancies at the early stages of disease. However, few biomarkers are clinically available. We designed this study to analyze the clinical application of the oncogene IMP3 in monitoring early malignancies in ovarian primary mucinous tumors. METHODS: We collected 250 samples of ovarian primary mucinous tumors along with the corresponding clinicopathological information between 2009 and 2015 at the Gynecology and Obstetrics Hospital of Fudan University and performed immunochemical assays...
2017: American Journal of Translational Research
https://www.readbyqxmd.com/read/28800942/plasma-and-ovarian-tissue-sphingolipids-profiling-in-patients-with-advanced-ovarian-cancer
#6
Paweł Knapp, Lubomir Bodnar, Agnieszka Błachnio-Zabielska, Magdalena Świderska, Adrian Chabowski
PURPOSE: The role of lipids in carcinogenesis through induction of abnormal cell lines in the human body is currently undisputable. Based on the literature, bioactive sphingolipids play an essential role in the development and progression of cancer and are involved in the metastatic process. The aim of this study was to determine the concentration of selected sphingolipids in patients with advanced ovarian cancer (AOC, FIGO III/IV, high grade ovarian cancer). METHODS: Seventy-four patients with ovarian cancer were enrolled...
August 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28799806/elevated-serum-level-of-ca125-is-a-biomarker-that-can-be-used-to-alter-prognosis-determined-by-brca-mutation-and-family-history-in-ovarian-cancer
#7
Weiling Liu, Zhizhong Wang, Jie Ma, Yangyang Hou, Jiuzhou Zhao, Bing Dong, Shichun Tu, Li Wang, Yongjun Guo
AIMS: In this study, we determined whether serum tumor markers (STMs), including CA125, are associated with BRCA mutation status and if they can be used prognostically in sporadic ovarian cancer (SOC) and familial ovarian cancer (FOC). METHODS: BRCA gene mutations were screened using next-generation sequencing (NGS) in 31 FOC and 66 SOC patients enrolled between 2013 and 2014. The serum levels of STM CEA, CA125, CA199, and HE4 were also measured in these patients to determine the prognostic potential of these markers and their association with BRCA mutations...
August 11, 2017: Genetic Testing and Molecular Biomarkers
https://www.readbyqxmd.com/read/28796802/the-prognostic-value-of-kras-mutation-by-cell-free-dna-in-cancer-patients-a-systematic-review-and-meta-analysis
#8
Rongyuan Zhuang, Song Li, Qian Li, Xi Guo, Feng Shen, Hong Sun, Tianshu Liu
KRAS mutation has been found in various types of cancer. However, the prognostic value of KRAS mutation in cell-free DNA (cfDNA) in cancer patients was conflicting. In the present study, a meta-analysis was conducted to clarify its prognostic significance. Literature searches of Cochrane Library, EMBASE, PubMed and Web of Science were performed to identify studies related to KRAS mutation detected by cfDNA and survival in cancer patients. Two evaluators reviewed and extracted the information independently. Review Manager 5...
2017: PloS One
https://www.readbyqxmd.com/read/28791360/classical-vegf-notch-and-ang-signalling-in-cancer-angiogenesis-alternative-approaches-and-future-directions-review
#9
Nunzia Caporarello, Gabriella Lupo, Melania Olivieri, Martina Cristaldi, Maria Teresa Cambria, Mario Salmeri, Carmelina Daniela Anfuso
Angiogenesis is the formation of new vessels starting from pre-existing vasculature. Tumour environment is characterized by 'aberrant angiogenesis', whose main features are tortuous and permeable blood vessels, heterogeneous both in their structure and in efficiency of perfusion and very different from normal vessels. Therapeutic strategies targeting the three pathways chiefly involved in tumour angiogenesis, VEGF, Notch and Ang signalling, have been identified to block the vascular supply to the tumour. However, phenomena of toxicity, development of primary and secondary resistance and hypoxia significantly blunted the effects of anti-angiogenic drugs in several tumour types...
August 7, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28790117/in-vivo-validation-of-papss1-3-phosphoadenosine-5-phosphosulfate-synthase-1-as-a-cisplatin-sensitizing-therapeutic-target
#10
Ada W Y Leung, Chansey J Veinotte, Nicole Melong, Min Hee Oh, Kent T J Chen, Katey Enfield, Ian Backstrom, Corinna Warburton, Donald T Yapp, Jason N Berman, Marcel B Bally, William W Lockwood
INTRODUCTION: Our previous screening efforts found that inhibition of PAPSS1 increases the potency of DNA damaging agents in non-small cell lung cancer (NSCLC) cell lines. Here, we explored the clinical relevance of PAPSS1 and further investigated it as a therapeutic target in pre-clinical model systems. METHODS: PAPSS1 expression and cisplatin IC50 values were assessed in 52 lung adenocarcinoma (LAC) cell lines. Effects of PAPSS1 inhibition on A549 cisplatin sensitivity under hypoxic and starvation conditions, in 3D spheroids, as well as in zebrafish and mouse xenografts, were evaluated...
August 8, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28783591/association-of-gene-polymorphisms-of-estrogen-receptor-follicle-stimulating-hormone-%C3%AE-and-leptin-with-follicular-cysts-in-large-white-sows
#11
Haotian Wang, Lu Chen, Yanwen Jiang, Shan Gao, Shuxiong Chen, Xue Zheng, Zhuo Liu, Yun Zhao, Hongjiao Li, Jiaxin Yu, Fengge Wang, Yating Liu, Chunjin Li, Xu Zhou
Ovarian follicular cysts are one of leading causes of infertility and financial loss in pig breeding program. This study was carried out to investigate the association between polymorphisms of estrogen receptor (ESR), follicle-stimulating hormone (FSH) β, and leptin genes and follicular cysts in sows. A total of 47 and 120 sows with follicular cysts and normal follicles, respectively, were selected to evaluate whether these candidate loci affect the formation of follicular cysts in sows. The polymorphisms of ESR, FSHβ, FSHβ/HaeIII and leptin genes were tested by PCR and PCR-RFLP methods...
April 7, 2017: Theriogenology
https://www.readbyqxmd.com/read/28782946/synergistic-tailoring-of-electrostatic-and-hydrophobic-interactions-for-rapid-and-specific-recognition-of-lysophosphatidic-acid-an-early-stage-ovarian-cancer-biomarker
#12
Ying Wang, Hanwen Pei, Yan Jia, Jianhua Liu, Zelun Li, Kelong Ai, Zhongyuan Lu, Lehui Lu
Early detection of ovarian cancer, the most lethal type of gynecologic cancer, can dramatically improve the efficacy of available treatment strategies. However, few screening tools exist for rapidly and effectively diagnosing ovarian cancer in early stages. Here, we present a facile 'lock-key' strategy, based on rapid, specific detection of plasma lysophosphatidic acid (LPA, an early-stage biomarker) with polydiacetylenes (PDAs)-based probe, for the early diagnosis of ovarian cancer. This strategy relies on specifically inserting LPA 'key' into the PDAs 'lock' through the synergistic electrostatic and hydrophobic interactions between them, leading to conformation transition of the PDA backbone with a concomitant blue-to-red color change...
August 7, 2017: Journal of the American Chemical Society
https://www.readbyqxmd.com/read/28778085/investigation-of-factors-affecting-the-efficacy-of-3c23k-a-human-monoclonal-antibody-targeting-misiir
#13
Sarah E Gill, Qing Zhang, Gary L Keeney, William A Cliby, S John Weroha
MISIIR is a potential target for ovarian cancer (OC) therapy due to its tissue-specific pattern of expression. 3C23K is a novel therapeutic monoclonal anti-MISIIR antibody designed to recruit effector cells and promote cell death through ADCC (antibody dependent cell-mediated cytotoxicity). Our objective was to determine the tolerability and efficacy of 3C23K in OC patient-derived xenografts (PDX) and to identify factors affecting efficacy. Quantitative RT-PCR, immunohistochemistry (IHC), and flow cytometry were used to categorize MISIIR expression in established PDX models derived from primary OC patients...
July 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28777143/assessing-tumor-infiltrating-lymphocytes-in-solid-tumors-a-practical-review-for-pathologists-and-proposal-for-a-standardized-method-from-the-international-immuno-oncology-biomarkers-working-group-part-2-tils-in-melanoma-gastrointestinal-tract-carcinomas-non
#14
Shona Hendry, Roberto Salgado, Thomas Gevaert, Prudence A Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen van de Vijver, M V Estrada, Paula I Gonzalez-Ericsson, Melinda Sanders, Benjamin Solomon, Cinzia Solinas, Gert G G M Van den Eynden, Yves Allory, Matthias Preusser, Johannes Hainfellner, Giancarlo Pruneri, Andrea Vingiani, Sandra Demaria, Fraser Symmans, Paolo Nuciforo, Laura Comerma, E A Thompson, Sunil Lakhani, Seong-Rim Kim, Stuart Schnitt, Cecile Colpaert, Christos Sotiriou, Stefan J Scherer, Michail Ignatiadis, Sunil Badve, Robert H Pierce, Giuseppe Viale, Nicolas Sirtaine, Frederique Penault-Llorca, Tomohagu Sugie, Susan Fineberg, Soonmyung Paik, Ashok Srinivasan, Andrea Richardson, Yihong Wang, Ewa Chmielik, Jane Brock, Douglas B Johnson, Justin Balko, Stephan Wienert, Veerle Bossuyt, Stefan Michiels, Nils Ternes, Nicole Burchardi, Stephen J Luen, Peter Savas, Frederick Klauschen, Peter H Watson, Brad H Nelson, Carmen Criscitiello, Sandra O'Toole, Denis Larsimont, Roland de Wind, Giuseppe Curigliano, Fabrice André, Magali Lacroix-Triki, Mark van de Vijver, Federico Rojo, Giuseppe Floris, Shahinaz Bedri, Joseph Sparano, David Rimm, Torsten Nielsen, Zuzana Kos, Stephen Hewitt, Baljit Singh, Gelareh Farshid, Sibylle Loibl, Kimberly H Allison, Nadine Tung, Sylvia Adams, Karen Willard-Gallo, Hugo M Horlings, Leena Gandhi, Andre Moreira, Fred Hirsch, Maria V Dieci, Maria Urbanowicz, Iva Brcic, Konstanty Korski, Fabien Gaire, Hartmut Koeppen, Amy Lo, Jennifer Giltnane, Marlon C Rebelatto, Keith E Steele, Jiping Zha, Kenneth Emancipator, Jonathan W Juco, Carsten Denkert, Jorge Reis-Filho, Sherene Loi, Stephen B Fox
Assessment of the immune response to tumors is growing in importance as the prognostic implications of this response are increasingly recognized, and as immunotherapies are evaluated and implemented in different tumor types. However, many different approaches can be used to assess and describe the immune response, which limits efforts at implementation as a routine clinical biomarker. In part 1 of this review, we have proposed a standardized methodology to assess tumor-infiltrating lymphocytes (TILs) in solid tumors, based on the International Immuno-Oncology Biomarkers Working Group guidelines for invasive breast carcinoma...
August 2, 2017: Advances in Anatomic Pathology
https://www.readbyqxmd.com/read/28774461/phase-ii-trial-of-bevacizumab-with-dose-dense-paclitaxel-as-first-line-treatment-in-patients-with-advanced-ovarian-cancer
#15
Nicole D Fleming, Robert L Coleman, Celestine Tung, Shannon N Westin, Wei Hu, Yunjie Sun, Priya Bhosale, Mark F Munsell, Anil K Sood
OBJECTIVES: To assess the tolerability and efficacy of bevacizumab with carboplatin and weekly paclitaxel as first-line adjuvant therapy for advanced stage ovarian cancer. METHODS: After IRB approval, this single-institution, phase II study enrolled patients with stage III or IV epithelial ovarian cancer after primary cytoreductive surgery to treatment with carboplatin (AUC 5), weekly paclitaxel (80mg/m2), and bevacizumab (15mg/kg) every 3weeks for at least 6cycles...
July 31, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28770105/multi-parametric-profiling-of-renal-cell-colorectal-and-ovarian-cancer-identifies-tumour-type-specific-stroma-phenotypes-and-a-novel-vascular-biomarker
#16
Sara Corvigno, Magnus Frödin, G Bea A Wisman, Hans W Nijman, Ate Gj Van der Zee, Karin Jirström, Björn Nodin, Ina Hrynchyk, David Edler, Peter Ragnhammar, Martin Johansson, Hanna Dahlstrand, Artur Mezheyeuski, Arne Östman
A novel set of integrated procedures for quantification of fibroblast-rich stroma and vascular characteristics has recently been presented allowing discovery of novel perivascular and stromal biomarkers in colorectal, renal cell, and ovarian cancer. In the present study, data obtained through these procedures from clinically well-annotated collections of these three tumour types have been used to address two novel questions. First, data have been used to investigate if the three tumour types demonstrate significant differences regarding features such as vessel diameter, vessel density, and perivascular marker expression...
July 2017: Journal of Pathology. Clinical Research
https://www.readbyqxmd.com/read/28767420/ccne1-expression-in-high-grade-serous-carcinoma-does-not-correlate-with-chemoresistance
#17
Stav Sapoznik, Sarit Aviel-Ronen, Keren Bahar-Shany, Oranit Zadok, Keren Levanon
Delayed diagnosis of ovarian cancer, as well as high recurrence rates and lack of personalized therapy options, are among the causes for poor survival figures. Much effort is made towards developing new therapeutic possibilities, however predictive biomarkers are still unavailable. CCNE1 amplification, occurring in ~20% of the high grade serous ovarian tumors, was previously proposed as a marker for platinum resistance and poor prognosis as well as for CDK2 inhibition. The current study aimed to examine the role of CCNE1 positive-immunostain as a predictor of first-line taxane-platinum chemoresistance...
July 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28761938/down-regulation-of-hk7-in-the-sera-of-breast-cancer-and-benign-breast-disease-patients
#18
Samina Ejaz, Faiz-Ul-Hassan Nasim, Muhammad Ashraf, Gulzar Ahmad
INTRODUCTION: Breast cancer is known as a leading cause of cancer-related death among women all over the world. Biomarkers facilitate diagnosis at the earliest possible stage and better prognosis of the disease. Hence, may help to improve the overall survival rate among breast cancer patients. To find a better diagnostic/prognostic marker we evaluated human tissue kallikrein 7 (hK7) as biomarker of breast cancer. hK7 is a secreted serine protease having chymotrypsin like activity. Serum hK7 is known to have aberrant expression in ovarian and prostate cancer but has not been yet studied in breast cancer...
July 2017: Heliyon
https://www.readbyqxmd.com/read/28758939/stonin-2-overexpression-is-correlated-with-unfavorable-prognosis-and-tumor-invasion-in-epithelial-ovarian-cancer
#19
Xiaoying Sun, Weijing Zhang, Han Li, Chunhao Niu, Yulan Ou, Libing Song, Yanna Zhang
Stonin 2 (STON2), which functions in adjusting endocytotic complexes, is probably involved in the monitoring of the internalization of dopamine D2 receptors which have an inhibitory action of dopamine on tumor progression. However, its clinical significance in tumor progression and prognosis remains unclear. We explored the association between STON2 and the clinicopathological characteristics of epithelial ovarian cancer (EOC). The STON2 levels in ovarian cancer and normal cell lines and tissues were detected by real-time PCR and Western blot analyses...
July 29, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28758506/exposure-to-modern-widespread-environmental-endocrine-disrupting-chemicals-and-their-effect-on-the-reproductive-potential-of-women-an-overview-of-current-epidemiological-evidence
#20
Anetta Karwacka, Dorota Zamkowska, Michał Radwan, Joanna Jurewicz
Growing evidence indicates that exposure to widespread, environmental contaminants called endocrine disruptors (EDCs) negatively affects animal and human reproductive health and has been linked to several diseases including infertility. This review aims to evaluate the impact of environmental exposure to endocrine disrupting chemicals [phthalates, parabens, triclosan, bisphenol A (BPA), organochlorine (PCBs) and perfluorinated (PFCs) compounds] on the reproductive potential among women, by reviewing most recently published literature...
July 31, 2017: Human Fertility: Journal of the British Fertility Society
keyword
keyword
120394
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"